19th Nov 2025 13:45
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) took place on 19 November 2025 in Stockholm. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below.
Resolution on (a) directed issue of shares (equalization issue), (b) amendment of the articles of association, and (c) reverse share split
The EGM resolved, in accordance with the proposal of the board of directors, to implement a reverse share split whereby 100 existing shares are consolidated into 1 share (1:100). The purpose of the reverse share split is to achieve an appropriate number of shares for the company. In order to achieve a total number of shares in the company that is evenly divisible by 100, the EGM resolved to issue a maximum of 896,242 new shares. The new shares shall only be subscribed for by Mangold Fondkommission AB and then allocated to shareholders whose shareholding is not evenly divisible by 100.
In addition, the EGM resolved to change the limits regarding the share capital and the number of shares in § 4 and § 5 of the company's articles of association so that the share capital shall be not less than SEK 120,000,000 and not more than SEK 480,000,000 and that the number of shares shall be not less than 12,000,000 and not more than 48,000,000.
The EGM further resolved to authorise the board of directors to set the record date for the reverse share split. Shareholders whose shareholding on the record date is not evenly divisible by 100 will receive the required number of shares free of charge. Further information on the procedure for the reverse share split will be published in connection with the board's decision on the record date.
Resolution on incentive program, including directed share issue and transfer of warrants
The EGM resolved on a long-term incentive program for employees in the company's wholly owned subsidiary Psyros Diagnostics Ltd by issuing so-called employee stock options. The employee stock option program includes a maximum of 100,000 employee stock options that may be offered to up to 21 employees in Psyros Diagnostics Ltd. Each employee stock option entitles the holder to acquire one new share in the company at an exercise price corresponding to the closing price of the company's share on NGM Nordic SME on the trading day before the day the employee stock option is granted.
In order to ensure the company's delivery of shares according to the employee stock option program, the EGM also resolved on a directed issue of 100,000 warrants to the company as well as approval of the transfer of warrants or shares to the participants in the incentive program.
For further information, please contact:Ulf Bladin, CEOE-mail: [email protected]Phone: +46 73 582 39 87Company website: www.prolightdx.com
About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction. The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.
AttachmentsExtraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025